Materials & DesignBioengineeringPeer-reviewed journal article
Mesenchymal Stem Cell Membrane Coating of Gelatin Nanospheres with Drug Release Ability for Inflammatory Tissue Targeting
Keisuke Moriyama, Mitsuru AndoiD, Kazuo SakuraiiD, Isamu AkibaiD, Yasuhiko Tabata
Abstract
Improvements in drug delivery have been achieved using nanospheres to prolong drug efficacy, accelerate absorption, and target tissues with ongoing inflammation. Although nanospheres have numerous pharmacokinetic advantages their tissue-targeting ability is poor. In contrast, mesenchymal stem cells (MSC) accumulate in high numbers in inflammatory tissues via the interaction between CXC-chemokine receptor 4 (CXCR4) expressed on MSC and stromal cell-derived factor 1 (SDF-1) secreted during inflammation. Therefore, this study investigated coating gelatin nanospheres (GNS) with MSC membranes (MSC-GNS) by extrusion and ultrasonication methods to enhance their inflammatory tissue tropism. {zeta}-potential measurements, western blotting and single-particle analysis of MSC-GNS by flow cytometry demonstrated the GNS surface was successfully coated with MSC membranes. Dot blotting demonstrated the binding ability of CXCR4 for SDF-1 was retained by MSC-GNS but absent for MSC-membrane-free GNS. The blood clearance of MSC-GNS was examined by their intravenous injection into mice. Although MSC-GNS and GNS were retained during the early distribution phase, MSC-GNS had a higher retention than GNS during the later elimination phase. Finally, we investigated the tissue distribution of MSC-GNS by intravenous injection into a mouse model of liver fibrosis and their potential therapeutic effect on liver fibrosis. We found a higher accumulation of MSC-GNS in inflamed livers and higher blood retention compared with MSC-membrane-free GNS. Furthermore, MSC-GNS loaded with an anti-fibrotic agent (LSKL, a 4-amino acid peptide that inhibits fibrosis progression) had an enhanced therapeutic effect on liver fibrosis than uncoated nanoparticles. Therefore, MSC-GNS might be a drug carrier with inflammatory tissue targeting and controlled drug release abilities. Synopsis Table of Contents Graphic O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=81 SRC="FIGDIR/small/657318v1_ufig1.gif" ALT="Figure 1"> View larger version (22K): org.highwire.dtl.DTLVardef@12331d8org.highwire.dtl.DTLVardef@19d7b43org.highwire.dtl.DTLVardef@79591org.highwire.dtl.DTLVardef@1ec805a_HPS_FORMAT_FIGEXP M_FIG C_FIG Mesenchymal stem cell membrane coated gelatin nanosphere as DDS nanocarrier
- Citations
- 1
- FWCI
- 1.52
- Field percentile
- top 28%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Novel application method for mesenchymal stem cell therapy utilizing its attractant-responsive accumulation property
- Directing Cells to Murine Atherosclerotic Aortic Lesions via Targeting Inflamed Circulatory Interface using Nanocarriers
Z.-J. Liu·Frontiers in Cardiovascular MedicinePeer-reviewed·Jun 24, 2025
- Licensing Microgels Prolong the Immunomodulatory Phenotype of Mesenchymal Stromal Cells
M. Patrick, R. T. Annamalai·bioRxiv·Jul 5, 2022
- Surface Functionalized RBC Membrane-Derived Nanoparticles for Targeted Drug Delivery to Attenuate Fatty Liver Disease
Alap Ali Zahid, Jiaqi Huang, … Arghya Paul·bioRxiv·Feb 25, 2026
- Interferon-gamma and TNF-alpha synergistically enhance the immunomodulatory capacity of Endometrial-Derived Mesenchymal Stromal Cell secretomes by differential microRNA and extracellular vesicle release
M. d. l. A. de Pedro, F. Marinaro, … J. G Casado·bioRxiv·Jun 10, 2021
- Intravenous administration of human umbilical cord mesenchymal stromal cells leads to an inflammatory response in the lung
A. H. Pichardo, B. Wilm, … P. Murray·bioRxiv·Sep 26, 2022